Precision Biosciences Inc
Research Precision Biosciences Inc (DTIL) on Bullrun: market cap USD 226.01M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerDTIL
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 226.01M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 32.65M
- Free cash flow-USD 13.44M
Valuation Snapshot
latest market cap is USD 226.01M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 34.26M | -USD 45.72M | -USD 65.93M | n/a | -3.56 | USD 110.82M | USD 28.81M | USD 92.25M |
| FY2024 | USD 68.70M | USD 7.17M | -USD 58.70M | n/a | 1.04 | USD 85.90M | USD 30.05M | USD 56.39M |
| FY2023 | USD 48.73M | -USD 61.32M | -USD 86.07M | n/a | -15.96 | USD 116.68M | USD 31.27M | USD 18.86M |
| FY2022 | USD 25.10M | -USD 111.64M | -USD 49.07M | n/a | -38.1 | USD 189.58M | USD 22.22M | USD 60.43M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 226.01M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 100.21M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 31.25M | 2.0 | n/a | n/a |
| 2023 | 2023-12-29 | USD 44.50M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 132.04M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 450.68M | n/a | n/a | n/a |
About Precision Biosciences Inc
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Precision Biosciences Inc's market cap?
Precision Biosciences Inc's market capitalization is USD 226.01M.
What does Precision Biosciences Inc do?
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair.